Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest LaboratoriesNSE:QUESTLAB -3.17%44 Price-to-Tangible-Book is 1.53 as of Jul. 29, 2026, which is 20% below its 10-year median of 1.91. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 44/100. The stock has 5 warning signs investors should review. Among 836 Drug Manufacturers companies, Quest Laboratories ranks better than 64.59% on this metric.
The historical rank and industry rank for Quest Laboratories's Price-to-Tangible-Book or its related term are showing as below:
NSE:QUESTLAB'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.53 Med: 1.91 Max: 2.05
Current: 1.53
During the past 6 years, Quest Laboratories's highest Price to Tangible Book Ratio was 2.05. The lowest was 1.53. And the median was 1.91.
NSE:QUESTLAB's Price-to-Tangible-Book is ranked better than 64.59% of 836
companies
in the Drug Manufacturers industry
Industry Median: 2.19
vs NSE:QUESTLAB: 1.53
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Quest Laboratories Price-to-Tangible-Book Related Terms
Quest Laboratories Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Quest Laboratories's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:QUESTLAB vs LLY, JNJ, ABBV: Price-to-Tangible-Book Comparison
For the Drug Manufacturers - General subindustry, Quest Laboratories's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Laboratories Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Quest Laboratories's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Quest Laboratories (NSE:QUESTLAB) has a Price-to-Tangible-Book of 1.53 as of Jul. 29, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Quest Laboratories and its competitors. This is 20% below median its historical median of 1.91. Over the past decade, Quest Laboratories' Price-to-Tangible-Book has ranged from 1.53 to 2.05. According to the industry distribution chart, Quest Laboratories ranks #296 out of 836 companies in the Drug Manufacturers industry, placing it in the top 35.4%.
Is Quest Laboratories' Price-to-Tangible-Book too high?
Quest Laboratories' current Price-to-Tangible-Book of 1.53 is 20% below median its 10-year median of 1.91. Over the past 10 years, this metric has ranged from a low of 1.53 to a high of 2.05. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.19. Quest Laboratories' value of 1.53 is 30.1% below this industry median. Based on the distribution chart, Quest Laboratories ranks #296 out of 836 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Quest Laboratories has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' Price-to-Tangible-Book compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #296 out of 836 companies for Price-to-Tangible-Book. This puts Quest Laboratories in the upper half of its industry. The industry median Price-to-Tangible-Book is 2.19. Quest Laboratories' value of 1.53 is 30.1% below this benchmark. Historically, Quest Laboratories' own Price-to-Tangible-Book has ranged from 1.53 to 2.05 over the past decade. While the company's 10-year median is 1.91 vs. the industry median of 2.19, Quest Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.19, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Laboratories's current Price-to-Tangible-Book of 1.53 is 30.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Quest Laboratories and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current Price-to-Tangible-Book is 1.53, which is 20% below median its own 10-year median of 1.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current Price-to-Tangible-Book of 1.53. The current Price-to-Tangible-Book is 1.53, which is 20% below median its 10-year median of 1.91 and 30.1% below the Drug Manufacturers industry median of 2.19. Quest Laboratories' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current Price-to-Tangible-Book is 1.53 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
44GF Score
Get the complete analysis for NSE:QUESTLAB
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QUESTLAB has been successfully added to your 
